Fig. 10

SI-2 treatment and SRC-3 KD change the cytokine profile in breast tumors to suppress tumor growth. A Luciferase activity in E0771 tumors from C57BL/6J mice treated with SI-2 (2.5 mg/kg) or vehicle. B Mouse cytokine array with cell lysates from E0771 tumors treated with SI-2 (2.5 mg/kg) or vehicle harvested from the mice shown in Panel A. C Quantification of the cytokine levels in Panel B is shown in the graph. D Inhibition of E0771 cell growth treated with different doses of IL-1RA but not Timp-1 compared to vehicle. The graph shows the quantification of the inhibition of cell growth by IL-1RA and Timp-1. E Mouse cytokine array with cell lysates from SRC-3 KD and control breast tumors. F Quantification of the cytokine levels in Panel E is shown in the graph. G–H Expression levels of Cxcl9 in SI-2-treated E0771 (G) and SRC-3 KD E0771 (H) breast tumor-bearing animals determined by IHC. Quantification of Cxcl9 levels in Panels g and h is shown in the graph. I–K The mRNA levels of Cxcl9 (I), Il-1ra (J), and Il-16 (K) in SRC-3 KD versus control KD E0771 cancer cells were determined